LFMD
LifeMD, Inc.
LFMD offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
NVO
Novo Nordisk A/S
NVO has the edge over LFMD overall, supported by stronger fundamentals and lower modeled downside.
LFMD Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Strong |
LFMD's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
LFMD PE Valuation
LFMD has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
LFMD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
LFMD has the edge over NVO on the outlook, with more favorable earnings and profitability expectations.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
LFMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.05 | +$0.11 |
| Q2 2026 | -$0.04 | +$0.16 |
| Q1 2026 | $0.06 | +$0.39 |
| Q4 2025 | $0.27 | +$0.80 |
| Q3 2025 | -$0.16 | +$0.48 |
| Q2 2025 | -$0.20 | +$0.50 |
| Q1 2025 | -$0.33 | +$0.41 |
| Q4 2024 | -$0.53 | +$0.17 |
LFMD lost $0.05 per share over the past year, a smaller loss than the year before, but its loss has widened in each of the last three quarters.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over LFMD on earnings quality, reporting a profit while its opponent remains loss making.
LFMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $44.6M | -26% |
| Q2 2026 | $47.3M | -24% |
| Q1 2026 | $50.2M | -24% |
| Q4 2025 | $7.1M | -89% |
| Q3 2025 | $60.2M | +13% |
| Q2 2025 | $62.2M | +23% |
| Q1 2025 | $65.7M | +49% |
| Q4 2024 | $64.3M | +43% |
LFMD's revenue has slid since its 2025 peak: $45M last quarter, down 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -10% | -6.7 points |
| Q2 2026 | -15% | -14 points |
| Q1 2026 | -18% | -22 points |
| Q4 2025 | -88% | -90 points |
| Q3 2025 | -3.3% | +5.5 points |
| Q2 2025 | -1.5% | +11 points |
| Q1 2025 | 3.9% | +18 points |
| Q4 2024 | 1.6% | +6.4 points |
LFMD's operating margin was −10% last quarter, down 6.7 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over LFMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over LFMD on profitability, with a higher operating margin.
LFMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.1M | -$176K |
| Q2 2026 | -$7M | -189% |
| Q1 2026 | $339.4K | -88% |
| Q4 2025 | -$3.4M | -356% |
| Q3 2025 | -$944.4K | -116% |
| Q2 2025 | $7.8M | +101% |
| Q1 2025 | $2.9M | -41% |
| Q4 2024 | $1.3M | -76% |
LFMD's free cash flow was −$11M over the past year, against $11M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over LFMD on cash generation, producing positive trailing cash flow while its opponent burns cash.
LFMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +394K shares |
| 1 year | +4.4% | +2M shares |
| 3 years | +40% | +13.7M shares |
| 5 years | +81% | +21.5M shares |
| Available history | +387% | +38.3M shares |
LFMD has 48M diluted shares, up 4.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2025 | $270,000 |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over LFMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
LFMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -9.6x | Net Cash |
LFMD has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
LFMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 27.5 | Oversold |
| Stochastic | 10.1 | Oversold |
LFMD's weekly RSI is 27 (oversold) and its Stochastic is 10 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
LFMD PE vs Healthcare Sector
| Metric | LFMD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LFMD has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
LFMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.39 | 31% below |
| 20 week MA | $3.14 | 47% below |
| 50 week MA | $3.54 | 53% below |
| 100 week MA | $5.40 | 69% below |
| 200 week MA | $5.43 | 69% below |
LFMD is in a downtrend: it's below all five of its weekly moving averages, and 69% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over LFMD on trend strength, trading above more of its moving averages.
LFMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.65 | $7.84 | +1106% |
| 2021 | $7.84 | $4.32 | -45% |
| 2022 | $4.32 | $2.05 | -53% |
| 2023 | $2.05 | $8.29 | +304% |
| 2024 | $8.29 | $5.22 | -37% |
| 2025 | $5.22 | $3.50 | -33% |
| 2026 YTD | $3.50 | $1.66 | -53% |
LFMD's yearly returns have swung widely, from +1106% in 2020 to −53% in 2022. It's down 53% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over LFMD on returns for 2026, with the stronger performance.